Aptose Biosciences Continues To Drift Without Thesis-Changing Data

It wouldn't be fair to say that there's been no clinical progress at Aptose Biosciences (NASDAQ:APTO) since my last update, but there certainly hasn't been enough to really sway investor sentiment, particularly in light of a more risk-averse biotech market. Aptose has two credible hematological oncology products in the pipeline, but there is a still lot of de-risking needed for both programs.

I do believe that the market is still heavily discounting the odds of clinical success here, but given the history of oncology drug development, and Aptose's own shaky clinical progress, that's not exactly unfair. I can still see a path toward a substantially higher fair value, but the reality is that investors are likely going to need to wait a year or more for sentiment-moving data.

Read more here: 

Aptose Biosciences Continues To Drift Without Thesis-Changing Data